Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 715

1.

Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding.

Inohara T, Liang L, Kosinski AS, Smith EE, Schwamm LH, Hernandez AF, Bhatt DL, Fonarow GC, Peterson ED, Xian Y.

Eur Stroke J. 2020 Mar;5(1):47-55. doi: 10.1177/2396987319871784. Epub 2019 Aug 28.

2.

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.

Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group.

N Engl J Med. 2020 Mar 28. doi: 10.1056/NEJMoa1915928. [Epub ahead of print]

PMID:
32222134
3.

PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.

Mentz RJ, DeVore AD, Tasissa G, Heitner JF, Piña IL, Lala A, Cole RT, Lanfear DD, Patel CB, Ginwalla M, Old W, Salacata AS, Bigelow R, Fonarow GC, Hernandez AF.

Am Heart J. 2020 Feb 28;223:98-105. doi: 10.1016/j.ahj.2019.12.024. [Epub ahead of print]

PMID:
32217365
4.

The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.

Bhatt AS, Ambrosy AP, Dunning A, DeVore AD, Butler J, Reed S, Voors A, Starling R, Armstrong PW, Ezekowitz JA, Metra M, Hernandez AF, O'Connor CM, Mentz RJ.

Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1795. [Epub ahead of print]

PMID:
32212297
5.

Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure.

Fudim M, Ali-Ahmed F, Parzynski CS, Ambrosy AP, Friedman DJ, Pokorney SD, Curtis JP, Fonarow GC, Masoudi FA, Hernandez AF, Al-Khatib SM.

JAMA Cardiol. 2020 Mar 25. doi: 10.1001/jamacardio.2020.0391. [Epub ahead of print]

PMID:
32211811
6.

Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure.

O'Connor KD, Brophy T, Fonarow GC, Blankstein R, Swaminathan RV, Xu H, Matsouaka RA, Albert NM, Velazquez EJ, Yancy CW, Heidenreich PA, Hernandez AF, DeVore AD.

Circ Heart Fail. 2020 Apr;13(4):e006963. doi: 10.1161/CIRCHEARTFAILURE.120.006963. Epub 2020 Mar 24.

PMID:
32207996
7.

Generating comparative evidence on new drugs and devices after approval.

Cipriani A, Ioannidis JPA, Rothwell PM, Glasziou P, Li T, Hernandez AF, Tomlinson A, Simes J, Naci H.

Lancet. 2020 Mar 21;395(10228):998-1010. doi: 10.1016/S0140-6736(19)33177-0. Review.

PMID:
32199487
8.

Time for NIH to lead on data sharing.

Sim I, Stebbins M, Bierer BE, Butte AJ, Drazen J, Dzau V, Hernandez AF, Krumholz HM, Lo B, Munos B, Perakslis E, Rockhold F, Ross JS, Terry SF, Yamamoto KR, Zarin DA, Li R.

Science. 2020 Mar 20;367(6484):1308-1309. doi: 10.1126/science.aba4456. No abstract available.

PMID:
32193313
9.

Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.

Marquis-Gravel G, Roe MT, Robertson HR, Harrington RA, Pencina MJ, Berdan LG, Hammill BG, Faulkner M, Muñoz D, Fonarow GC, Nallamothu BK, Fintel DJ, Ford DE, Zhou L, Daugherty SE, Nauman E, Kraschnewski J, Ahmad FS, Benziger CP, Haynes K, Merritt JG, Metkus T, Kripalani S, Gupta K, Shah RC, McClay JC, Re RN, Geary C, Lampert BC, Bradley SM, Jain SK, Seifein H, Whittle J, Roger VL, Effron MB, Alvarado G, Goldberg YH, VanWormer JL, Girotra S, Farrehi P, McTigue KM, Rothman R, Hernandez AF, Jones WS.

JAMA Cardiol. 2020 Mar 18. doi: 10.1001/jamacardio.2020.0116. [Epub ahead of print]

PMID:
32186653
10.

Machine learning to predict venous thrombosis in acutely ill medical patients.

Nafee T, Gibson CM, Travis R, Yee MK, Kerneis M, Chi G, AlKhalfan F, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Goldhaber SZ.

Res Pract Thromb Haemost. 2020 Jan 21;4(2):230-237. doi: 10.1002/rth2.12292. eCollection 2020 Feb.

11.

Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.

Bethel MA, Stevens SR, Buse JB, Choi J, Gustavson SM, Iqbal N, Lokhnygina Y, Mentz RJ, Patel RA, Öhman P, Schernthaner G, Lecube A, Hernandez AF, Holman RR.

Circulation. 2020 Feb 26. doi: 10.1161/CIRCULATIONAHA.119.043353. [Epub ahead of print]

PMID:
32098501
12.

Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.

Cooper LB, Benson L, Mentz RJ, Savarese G, DeVore AD, Carrero JJ, Dahlström U, Anker SD, Lainscak M, Hernandez AF, Pitt B, Lund LH.

Eur J Heart Fail. 2020 Feb 20. doi: 10.1002/ejhf.1757. [Epub ahead of print]

PMID:
32078214
13.

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.

O'Meara E, McDonald M, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Grzeslo A, Heckman GA, Howlett JG, Koshman SL, Lepage S, Mielniczuk LM, Moe GW, Swiggum E, Toma M, Virani SA, Zieroth S, De S, Matteau S, Parent MC, Asgar AW, Cohen G, Fine N, Davis M, Verma S, Cherney D, Abrams H, Al-Hesayen A, Cohen-Solal A, D'Astous M, Delgado DH, Desplantie O, Estrella-Holder E, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, LeBlanc MH, Lee D, Masoudi FA, McKelvie RS, Rajda M, Ross HJ, Sussex B.

Can J Cardiol. 2020 Feb;36(2):159-169. doi: 10.1016/j.cjca.2019.11.036.

PMID:
32036861
14.

Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure.

Kelly JP, Ballew NG, Lin L, Hammill BG, Stivland TM, Jones PW, Curtis LH, Hernandez AF, Greiner MA, Atwater BD.

JACC Heart Fail. 2020 Apr;8(4):280-288. doi: 10.1016/j.jchf.2019.10.009. Epub 2020 Feb 5.

PMID:
32035894
15.

Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines - Heart Failure Program).

Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, Bhatt DL, Allen LA, Peterson PN, Ho PM, Lewis WR, Hernandez AF, Fonarow GC, Piccini JP.

Am J Cardiol. 2020 Mar 15;125(6):894-900. doi: 10.1016/j.amjcard.2019.12.025. Epub 2019 Dec 30.

PMID:
31980141
16.

Considerations for using distributed research networks to conduct aspects of randomized trials.

Marsolo KA, Brown JS, Hernandez AF, Hammill BG, Raman SR, Syat B, Platt R, Curtis LH.

Contemp Clin Trials Commun. 2020 Jan 2;17:100515. doi: 10.1016/j.conctc.2019.100515. eCollection 2020 Mar.

17.

A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF).

Masson R, Ambrosy AP, Kheder K, Fudim M, Clare RM, Coles A, Hernandez AF, Starling RC, Ezekowitz JA, O'Connor CM, Mentz RJ.

J Cardiovasc Transl Res. 2020 Jan 13. doi: 10.1007/s12265-020-09954-x. [Epub ahead of print]

PMID:
31933144
18.

Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.

Patel RB, Mehta R, Redfield MM, Borlaug BA, Hernandez AF, Shah SJ, Dubin RF.

J Card Fail. 2020 Mar;26(3):233-242. doi: 10.1016/j.cardfail.2020.01.003. Epub 2020 Jan 11.

PMID:
31931098
19.

Application of novel technologies and mechanistic data for risk assessment under the real-life risk simulation (RLRS) approach.

Hernández AF, Docea AO, Goumenou M, Sarigiannis D, Aschner M, Tsatsakis A.

Food Chem Toxicol. 2020 Mar;137:111123. doi: 10.1016/j.fct.2020.111123. Epub 2020 Jan 8. No abstract available.

PMID:
31926207
20.

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.

Idzerda NMA, Clegg LE, Hernandez AF, Bakris G, Penland RC, Boulton DW, Bethel MA, Holman RR, Heerspink HJL.

Diabetes Obes Metab. 2020 May;22(5):798-806. doi: 10.1111/dom.13958. Epub 2020 Feb 3.

PMID:
31912603
21.

Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.

Shah S, Liang L, Kosinski A, Hernandez AF, Schwamm LH, Smith EE, Fonarow GC, Bhatt DL, Feng W, Peterson ED, Xian Y.

Circ Cardiovasc Qual Outcomes. 2020 Jan;13(1):e006031. doi: 10.1161/CIRCOUTCOMES.119.006031. Epub 2020 Jan 6.

PMID:
31903770
22.

Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.

Standl E, Stevens SR, Lokhnygina Y, Bethel MA, Buse JB, Gustavson SM, Maggioni AP, Mentz RJ, Hernandez AF, Holman RR; EXSCEL Study Group.

Diabetes Care. 2020 Mar;43(3):643-652. doi: 10.2337/dc19-1079. Epub 2019 Dec 27.

PMID:
31882409
23.

Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.

Patel RB, Alenezi F, Sun JL, Alhanti B, Vaduganathan M, Oh JK, Redfield MM, Butler J, Hernandez AF, Velazquez EJ, Shah SJ.

J Card Fail. 2020 Mar;26(3):270-275. doi: 10.1016/j.cardfail.2019.12.001. Epub 2019 Dec 17.

PMID:
31857197
24.

Biomonitoring of 45 inorganic elements measured in plasma from Spanish subjects: A cross-sectional study in Andalusian population.

Henríquez-Hernández LA, Romero D, González-Antuña A, Gonzalez-Alzaga B, Zumbado M, Boada LD, Hernández AF, López-Flores I, Luzardo OP, Lacasaña M.

Sci Total Environ. 2020 Mar 1;706:135750. doi: 10.1016/j.scitotenv.2019.135750. Epub 2019 Nov 26.

PMID:
31841855
25.

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

Butler J, Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL Jr, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Stockbridge N, O'Connor CM.

Circulation. 2019 Dec 17;140(25):2108-2118. doi: 10.1161/CIRCULATIONAHA.119.042155. Epub 2019 Dec 16.

PMID:
31841369
26.

From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies.

DeVore AD, Hernandez AF.

JACC Heart Fail. 2020 Jan;8(1):55-56. doi: 10.1016/j.jchf.2019.09.010. Epub 2019 Dec 11. No abstract available.

PMID:
31838033
27.

Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.

Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, Butler J, Ezekowitz J, Hernandez AF, Koglin J, Lam CSP, Ponikowski P, Roessig L, Voors AA, O'Connor CM, Armstrong PW; VICTORIA Study Group.

Eur J Heart Fail. 2019 Dec;21(12):1596-1604. doi: 10.1002/ejhf.1664. Epub 2019 Dec 9.

PMID:
31820546
28.

Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure.

Kelly JP, DeVore AD, Wu J, Hammill BG, Sharma A, Cooper LB, Felker GM, Piccini JP, Allen LA, Heidenreich PA, Peterson ED, Yancy CW, Fonarow GC, Hernandez AF.

J Am Heart Assoc. 2019 Dec 17;8(24):e011560. doi: 10.1161/JAHA.118.011560. Epub 2019 Dec 10.

29.

Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Reed SD, Li Y, Dakin HA, Becker F, Leal J, Gustavson SM, Kartman B, Wittbrodt E, Mentz RJ, Pagidipati NJ, Bethel MA, Gray AM, Holman RR, Hernandez AF; EXSCEL Study Group.

Diabetes Care. 2020 Feb;43(2):374-381. doi: 10.2337/dc19-0950. Epub 2019 Dec 5.

PMID:
31806653
30.

Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?

Fudim M, Kelly JP, Jones AD, AbouEzzeddine OF, Ambrosy AP, Greene SJ, Reddy YNV, Anstrom KJ, Alhanti B, Lewis GD, Hernandez AF, Felker GM.

Am Heart J. 2020 Feb;220:97-107. doi: 10.1016/j.ahj.2019.11.006. Epub 2019 Nov 16.

PMID:
31805424
31.

Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018.

Panozzo CA, Curtis LH, Marshall J, Fine L, Wells BL, Brown JS, Haynes K, Pawloski PA, Hernandez AF, Malek S, Syat B, Platt R.

PLoS One. 2019 Dec 5;14(12):e0223515. doi: 10.1371/journal.pone.0223515. eCollection 2019.

32.

Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF.

DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, Butler J, Piña IL, Heidenreich PA, Allen LA, Yancy CW, Cooper LB, Felker GM, Kaltenbach LA, McRae AT, Lanfear DE, Harrison RW, Kociol RD, Disch M, Ariely D, Miller JM, Granger CB, Hernandez AF.

Am Heart J. 2020 Feb;220:41-50. doi: 10.1016/j.ahj.2019.09.012. Epub 2019 Oct 23.

PMID:
31770656
33.

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.

Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, Hernandez AF, Holman RR.

Diabetes Care. 2020 Feb;43(2):446-452. doi: 10.2337/dc19-1065. Epub 2019 Nov 22.

PMID:
31757838
34.

Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.

Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, Pagidipati NJ, Sattar N, Holman RR, Hernandez AF, Mentz RJ, Patel MR, Jones WS.

Circ Cardiovasc Interv. 2019 Dec;12(12):e008018. doi: 10.1161/CIRCINTERVENTIONS.119.008018. Epub 2019 Nov 22.

PMID:
31752517
35.

Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.

Sharma A, Wu J, Ezekowitz JA, Felker GM, Udell JA, Heidenreich PA, Fonarow GC, Mahaffey KW, Hernandez AF, DeVore AD.

ESC Heart Fail. 2020 Feb;7(1):274-278. doi: 10.1002/ehf2.12528. Epub 2019 Nov 20.

36.

Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?-A Call for a Randomized Clinical Trial.

Yancy CW, Fonarow GC, Hernandez AF.

JAMA Cardiol. 2019 Nov 18. doi: 10.1001/jamacardio.2019.5019. [Epub ahead of print] No abstract available.

PMID:
31738365
37.

Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study.

Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E.

J Card Fail. 2019 Nov 2. pii: S1071-9164(19)30584-6. doi: 10.1016/j.cardfail.2019.10.011. [Epub ahead of print]

PMID:
31682908
38.

Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).

Giblin EM, Adams KF Jr, Hill L, Fonarow GC, Williams FB, Sharma PP, Albert NM, Butler J, DeVore AD, Duffy CI, Hernandez AF, McCague K, Spertus JA, Thomas L, Patterson JH.

Am J Cardiol. 2019 Dec 15;124(12):1900-1906. doi: 10.1016/j.amjcard.2019.09.020. Epub 2019 Sep 26.

PMID:
31679641
39.

The Future of Wearables in Heart Failure Patients.

DeVore AD, Wosik J, Hernandez AF.

JACC Heart Fail. 2019 Nov;7(11):922-932. doi: 10.1016/j.jchf.2019.08.008. Review.

PMID:
31672308
40.

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.

Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, Gustavson S, Sjöström CD, Ruggles JA, Hernandez AF, Buse JB, Mentz RJ, Holman RR.

Cardiovasc Diabetol. 2019 Oct 22;18(1):138. doi: 10.1186/s12933-019-0942-x.

41.

PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure.

Sayeed S, Fudim M, Devore AD, Xu H, Matsouaka RA, Heidenreich PA, Yancy CW, Fonarow GC, Hernandez AF.

J Card Fail. 2019 Dec;25(12):1009-1011. doi: 10.1016/j.cardfail.2019.10.003. Epub 2019 Oct 15. No abstract available.

PMID:
31626949
42.

Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF.

Greene SJ, DeVore AD, Sheng S, Fonarow GC, Butler J, Califf RM, Hernandez AF, Matsouaka RA, Samman Tahhan A, Thomas KL, Vaduganathan M, Yancy CW, Peterson ED, O'Connor CM, Mentz RJ.

JACC Heart Fail. 2019 Nov;7(11):980-992. doi: 10.1016/j.jchf.2019.07.011. Epub 2019 Oct 9.

PMID:
31606362
43.

The Hospital Readmissions Reduction Program: Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper.

Psotka MA, Fonarow GC, Allen LA, Joynt Maddox KE, Fiuzat M, Heidenreich P, Hernandez AF, Konstam MA, Yancy CW, O'Connor CM.

JACC Heart Fail. 2020 Jan;8(1):1-11. doi: 10.1016/j.jchf.2019.07.012. Epub 2019 Oct 9. Review.

PMID:
31606360
44.

Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals.

Martin AC, Huang W, Goldhaber SZ, Hull RD, Hernandez AF, Gibson CM, Anderson FA, Cohen AT.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619880008. doi: 10.1177/1076029619880008.

45.

Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.

Marquis-Gravel G, Roe MT, Harrington RA, Muñoz D, Hernandez AF, Jones WS.

Circulation. 2019 Sep 24;140(13):1115-1124. doi: 10.1161/CIRCULATIONAHA.119.040205. Epub 2019 Sep 23.

PMID:
31545683
46.

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.

Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ.

Circulation. 2019 Nov 12;140(20):1613-1622. doi: 10.1161/CIRCULATIONAHA.119.041659. Epub 2019 Sep 23.

47.

Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.

Voors AA, Bax JJ, Hernandez AF, Wirtz AB, Pap AF, Ferreira AC, Senni M, van der Laan M, Butler J; PANTHEON Investigators.

Eur J Heart Fail. 2019 Nov;21(11):1426-1433. doi: 10.1002/ejhf.1591. Epub 2019 Sep 16.

PMID:
31523892
48.

Critical assessment and integration of separate lines of evidence for risk assessment of chemical mixtures.

Hernandez AF, Buha A, Constantin C, Wallace DR, Sarigiannis D, Neagu M, Antonijevic B, Hayes AW, Wilks MF, Tsatsakis A.

Arch Toxicol. 2019 Oct;93(10):2741-2757. doi: 10.1007/s00204-019-02547-x. Epub 2019 Sep 13.

PMID:
31520250
49.

Virgin Olive Oil and Health: Summary of the III International Conference on Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018.

Gaforio JJ, Visioli F, Alarcón-de-la-Lastra C, Castañer O, Delgado-Rodríguez M, Fitó M, Hernández AF, Huertas JR, Martínez-González MA, Menendez JA, Osada J, Papadaki A, Parrón T, Pereira JE, Rosillo MA, Sánchez-Quesada C, Schwingshackl L, Toledo E, Tsatsakis AM.

Nutrients. 2019 Sep 1;11(9). pii: E2039. doi: 10.3390/nu11092039. Review.

50.

Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial.

Blumer V, Greene SJ, Sun JL, Bart BA, Ambrosy AP, Butler J, DeVore AD, Fudim M, Hernandez AF, McNulty SE, Felker GM, Mentz RJ.

Eur J Heart Fail. 2019 Nov;21(11):1472-1476. doi: 10.1002/ejhf.1592. Epub 2019 Aug 27. No abstract available.

PMID:
31452311

Supplemental Content

Loading ...
Support Center